MDGEF (Medigene AG) 3-1 Month Momentum %: N/A% (As of Aug. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MDGEF Medigene AG MDGEF
12 GF Score
Price $2.59
View Full Analysis

What is Medigene AG 3-1 Month Momentum %?

Medigene AG MDGEF 12 3-1 Month Momentum % is N/A% as of Aug. 14, 2026. GuruFocus rates MDGEF with a GF Score™ of 12/100.

3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-14), Medigene AG's 3-1 Month Momentum % is N/A%.

The industry rank for Medigene AG's 3-1 Month Momentum % or its related term are showing as below:

MDGEF's 3-1 Month Momentum % is not ranked *
in the Biotechnology industry.
Industry Median: -8.13
* Ranked among companies with meaningful 3-1 Month Momentum % only.

Medigene AG  (OTCPK:MDGEF) 3-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Medigene AG 3-1 Month Momentum % Related Terms

MDGEF vs VRTX, REGN, ALNY: 3-1 Month Momentum % Comparison

For the Biotechnology subindustry, Medigene AG's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medigene AG 3-1 Month Momentum % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medigene AG's 3-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Medigene AG's 3-1 Month Momentum % falls into.


MDGEF
12GF Score
Medigene AG MDGEF
3-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medigene AG  (OTCPK:MDGEF) 3-1 Month Momentum % Calculation

3-1 Month Momentum % is calculated as following:

3-1 Month Momentum %=( Price 1-month ago / Price 3-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 3-1 Month Momentum % →
What does a 3-1 Month Momentum % of N/A% mean?
Medigene AG (MDGEF) has a 3-1 Month Momentum % of N/A% as of Aug. 14, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Medigene AG and its competitors.
Is Medigene AG's 3-1 Month Momentum % too high?
Medigene AG's current 3-1 Month Momentum % is N/A%. Overall, Medigene AG has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Medigene AG's 3-1 Month Momentum % compare to VRTX and REGN?
Medigene AG's 3-1 Month Momentum % of N/A% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Medigene AG and its competitors. Medigene AG's current 3-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medigene AG stock overvalued right now?
Medigene AG (MDGEF) has a current 3-1 Month Momentum % of N/A%. The current 3-1 Month Momentum % is N/A%. Medigene AG's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Medigene AG (MDGEF), the current 3-1 Month Momentum % is N/A% as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Medigene AG Business Description

Address Lochhamer Strasse 11, Martinsried, Planegg, BY, DEU, 82152
Medigene AG is an immuno-oncology biotechnology company. focused on developing differentiated T Cell Receptor engineered T cell (TCR-T) therapies for the treatment of multiple solid tumor indications with a high unmet medical need. The operating segments of the organization are Immunotherapies and Other products. Immunotherapies consist of T-cell receptor-based adoptive T-cell therapy and DC vaccines. The group operates in the United States, Germany, and Asia, of which the majority of the revenue is derived from operations in Germany.
12GF Score

Get the complete analysis for MDGEF

3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.59
Price